Novartis Receives Full FDA Approval for Fabhalta in Treating IgAN
Novartis (NVS) has received full approval from the U.S. Food and Drug Administration (FDA) for its therapy, Fabhalta (iptacopan), to treat primary immunoglobulin A nephropathy (IgAN). This marks a significant milestone in addressing this autoimmune kidney disease.
Tickers: $NVS